GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its
NICHI BRITE (AFO-202), one of the NICHI GLUCAN brand products for overseas markets, has undergone clinical tri
GNC’s activities are introduced in the Japan Cabinet Office’s site ‘Invest Japan’
This is the research on the potential of beta-glucan for autism
A breakthrough achievement on miRNA140 is published in Medicine Innovates
An interview was published in a feature story in Bloomburg
GN Corporation participates in the “Autism Sunday” to be held on February 13, 2022
The NCRM NICHE 2021 is held virtually on 17 Oct 2021
This is the study on Beta glucan food supplements potential in Covid-19 patients
Manuscript published in Stem Cell Reviews and Reports
Technology transfer on cell therapy to Vietnam by GN Corporation
Webiner on Cell Therapy Approaches for Urethral Stricture is held
